EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A SUB-ANALYSIS OF THE EMPA-REG OUTCOME TRIAL